About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 4 from 2024 or later, 5 in Q1 journals, collectively cited 447 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 51 papers retrieved from a database of over 500 million.
Sources used in this answer
CAR T Cells and T-Cell Therapies for Cancer
The paper reviews engineered T-cell therapies, including CAR T cells, and their applications in various cancers. It highlights recent approvals for solid tumors such as melanoma and synovial cell sarcoma, indicating relevance to moving beyond adult rare-sarcoma niches.
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors
The paper investigates adoptive cellular therapy using autologous tumor-infiltrating lymphocytes and T-cell receptor–engineered T cells targeting shared p53 neoantigens in human solid tumors. It reports clinical outcomes in patients with various solid tumors, including breast cancer. However, the paper does not address rare sarcoma, which limits its relevance to that specific context.
Potential Mechanisms for Immunotherapy Resistance in Adult Soft-Tissue Sarcoma
The paper reviews immunotherapy resistance mechanisms in adult soft-tissue sarcoma, a rare malignancy. It discusses challenges in immunotherapy application but does not explore engineered T-cell therapy approaches, limiting its relevance to that specific aspect.
CAR-T therapy in solid tumors
The paper reviews CAR-T therapy advancements and challenges in treating solid tumors, emphasizing strategies to improve efficacy. While it addresses engineered T-cell therapy for solid tumors, it does not cover rare sarcoma or related patient populations.
Engineering TME-gated inducible CAR-T cell therapy for solid tumors
The paper presents an innovative CAR-T cell therapy strategy for solid tumors, specifically using a xenograft prostate tumor model. It does not address rare sarcoma or related patient populations, limiting its relevance to that context.